Achillion Pharma (NASDAQ:ACHN) target price raised to $5.00, issued a report today by Chardan Capital
- Updated: September 23, 2016
Achillion Pharma (NASDAQ:ACHN) had its target price raised to $5.00 by Chardan Capital in a report released Friday September 23, 2016. The new target price indicates a possible downside of -0.41% based on the company's last closing price.
Previously on Thursday September 22, 2016, Wedbush reported on Achillion Pharma (NASDAQ:ACHN) raised the target price from $0.00 to $13.00. At the time, this indicated a possible upside of 0.54%.
Just yesterday Achillion Pharma (NASDAQ:ACHN) traded 4.20% higher at $8.44. ACHN’s 50-day average is $8.49 and its two hundred day average is $8.40. The last closing price is up 0.47% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Volume of trade was up over the average, with 2,036,821 shares of ACHN changing hands over the typical 1,365,310
With a total market value of $0, Achillion Pharma has P/E ratio of 172.24 with a one year low of $5.57 and a one year high of $10.95 .
Also covering Achillion Pharma's price target, a total of 5 firms have reported on the company. The average stock price target is $9.40 with 2 brokerages rating the company a strong buy, one equity analyst rating the company a buy, three analysts rating the stock a hold, 1 equity analyst rating the company a underperform, and lastly 0 brokers rating the stock a sell.
General Company Details For Achillion Pharma (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.